Promoting axon regeneration by activation of the Smad1 signaling pathway

描述（由申请人提供）：脊髓损伤切断了大脑和脊髓之间的连接，导致破坏性后果，如损伤部位以下的感觉和运动控制丧失。永久性神经缺陷背后的原因是成年哺乳动物神经元在损伤后无法再生。成功的轴突再生的一个策略是增强受损神经元的内在轴突生长能力。这需要定义分子通路，可以促进轴突生长，并建立治疗方法来打开它们on. Recently，我们已经证明了一个关键作用的Smad 1，转录因子，在切换成人感觉神经元到一个活跃的生长状态在体外。该提案的重点是使用脊髓损伤的啮齿动物模型的Smad 1通路的体内功能。我们建议测试的中心假设，激活Smad 1在成年感觉神经元促进轴突再生的上行感觉通路。这一假设得到了我们的初步研究的支持，这些研究表明，在背根神经节中，Smad 1的激活可以促进感觉轴突再生。这是使用微创和临床适用的体内基因操作方法在我的实验室专门为体内脊髓研究。基于这些令人兴奋的结果，目的1将研究DRG神经元中Smad 1的激活机制。这包括BMP依赖性和非依赖性途径。一种新的激酶，Mps 1，在介导轴突生长和Smad 1-在连接区和C-末端的差异磷酸化的功能的作用将被研究。将确定Smad 1的下游靶点。目的2侧重于使用啮齿动物脊髓损伤模型的体内测定，以比较通过BMP依赖性和非依赖性途径激活Smad 1的再生表型。AAV-BMP的治疗潜力将通过在损伤后注射AAV来进一步评估。总之，这些研究有望为操纵Smad 1通路对脊髓损伤后轴突再生的治疗潜力提供见解。此外，该提议还旨在确定激活Smad 1或作为下游效应物的新分子靶标。最后，体内研究将验证一种微创和临床适用的治疗方法，可以很容易地转化为脊髓损伤患者的临床试验。 公共卫生相关性：脊髓损伤导致感觉和运动功能丧失。然而，迄今为止，没有临床治疗存在促进轴突的功能性再生。本文提出的研究有望为操纵Smad 1通路对轴突再生的治疗潜力提供重要见解，并验证临床相关且易于翻译的治疗策略，以促进脊髓损伤患者的功能恢复。

DESCRIPTION (provided by applicant): Spinal cord injury severs the connections between the brain and the spinal cord, which causes devastating outcomes such as loss of sensory and motor controls below the lesion site. The reason behind the permanent neurological deficit is that adult mammalian neurons fail to regenerate after injury. One strategy for successful axon regeneration is to enhance the intrinsic axon growth capability of injured neurons. This requires defining molecular pathways that can promote axon outgrowth and establishing therapeutic approaches to turn them on. Recently, we have demonstrated a key role of Smad1, a transcription factor, in switching adult sensory neurons into an active growth state in vitro. This proposal focuses on the in vivo function of the Smad1 pathway using rodent models of spinal cord injury. We propose to test the central hypothesis that activation of Smad1 in adult sensory neurons promotes axon regeneration of ascending sensory pathway. This hypothesis is supported by our pilot studies that demonstrate robust sensory axon regeneration with activation of Smad1 in DRGs. This was achieved using a minimally invasive and clinically applicable in vivo gene manipulation method designed in my laboratory specifically for in vivo spinal cord research. Based on these exciting results, Aim 1 will investigate the Smad1 activation mechanisms in DRG neurons. This includes BMP-dependent and -independent pathways. The role of a novel kinase, Mps1, in mediating axonal growth and the function of the differential phosphorylation of Smad1-at the linker area and C- terminus will be studied. The downstream targets of Smad1 will be identified. Aim 2 focuses on in vivo assays using rodent models of spinal cord injury to compare the regenerative phenotypes of Smad1 activation by BMP-dependent and -independent pathways. Therapeutic potential of AAV-BMP will be further evaluated by injecting AAV after injury. In summary, these studies are expected to provide insights into the therapeutic potential of manipulating the Smad1 pathway on axon regeneration after spinal cord injury. Furthermore, this proposal also aims at identifying novel molecular targets that activate Smad1 or act as downstream effectors. Finally the in vivo studies will validate a minimally invasive and clinically applicably therapeutic approach that can be readily translated into clinical trials for spinal cord injury patients. PUBLIC HEALTH RELEVANCE: Spinal cord injury results in loss of sensory and motor function. Yet, to date, no clinical treatment exists to promote functional regeneration of axons. The studies proposed here are expected to provide important insights into the therapeutic potential of manipulating the Smad1 pathway on axonal regeneration, and to validate a clinically relevant and readily translatable therapeutic strategy to promote functional recovery in spinal cord injury patients.